Trial Profile
Compassionate use of gemtuzumab ozogamicin in children with relapsed and refractory acute myeloid leukemia
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Acronyms AML-BFM
- 25 Jan 2017 New trial record
- 06 Dec 2016 Results of a retrospective analysis (n=88) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.